[1]
Choi HY, Siddique HR, Zheng M, et al. p53 Destabilizing protein skews asymmetric division and enhances NOTCH activation to direct self-renewal of TICs. Nat Commun 2020; 11: 3084.
[2]
Jameel M, Jamal K, Alam MF, Yonus H, Ameen F, Siddique HR. Interaction of thiamethoxam with DNA: Hazardous effect on biochemical and biological parameters of the exposed organism. Chemosphere 2020; 254126875
[3]
Ganaie A, Mansini AP, Hussain T, et al. Biopsy-S100A4 and serum-S100A4 alterations predict poor outcome in prostate cancer: Clinical significance of anti-S100A4 antibody therapy. Mol Cancer Ther 2020.
[http://dx.doi.org/10.1158/1535-7163.MCT-20-0410]
[http://dx.doi.org/10.1158/1535-7163.MCT-20-0410]
[4]
Ganaie AA, Siddique HR, Parray A, et al. A novel terpenoid class for prevention and treatment of KRAS-driven cancers: Comprehensive analysis using in situ, in vitro and in vivo model systems. Mol Carcinog 2020; 59: 886-96.
[5]
Arjmand F, Afsan Z, Sharma S, et al. Recent Advances in Metalodrug-like Molecules targetting non-coding RNAs (ncRNAs) in cancer Chemotherapy. Coord Chem Rev 2019; 387: 47-59.
[6]
Ganaie AA, Beigh FH, Astone M, et al. BMI1 drives metastasis of prostate cancer in Caucasian and African-American men and is a potential therapeutic target: hypothesis tested in race-specific models. Clin Cancer Res 2018; 24: 6421-32.
[7]
Siddique HR, Feldman DE, Chen C, Punj V, Tokumitsu H, Machida K. NUMB phosphorylation destabilizes p53 and promotes self-renewal of tumor-initiating cells by NANOG-dependent mechanism in liver cancer. Hepatology 2015; 62: 1466-79.
[8]
Parray A, Siddique HR, Kuriger J, et al. ROBO1, a tumor suppressor and critical molecular barrier for localized tumor cells to acquire invasive phenotype: Study in African-American and Caucasian prostate cancer models. Int J Cancer 2014; 135: 2493-506.
[9]
Siddique HR, Adhami VM, Parray A, et al. The S100A4 oncoprotein promotes prostate tumorigenesis in a transgenic mouse model: Regulating NFκB through the RAGE receptor. Genes Cancer 2013; 4: 224-34.
[10]
Siddique HR, Liao JD, Mishra SK, et al. Epicatechin-rich cocoa polyphenol inhibits Kras-activated pancreatic ductal carcinoma cell growth in vitro and in a mouse model. Int J Cancer 2012; 131: 1720-31.
[11]
Siddique HR, Adhami VM, Parray A, et al. The S100A4 oncoprotein promotes prostate tumorigenesis in a transgenic mouse model: Regulating NFκB through the RAGE receptor. Genes Cancer 2013; 4: 224-34.
[12]
Siddique HR, Saleem M. Role of BMI1 in cancer recurrence and chemoresistance: Preclinical and clinical evidence. Stem Cells 2012; 30: 372-8.
[13]
Siddique HR, Mishra SK, Karnes RJ, Saleem M. Lupeol, a novel androgen receptor inhibitor: Implications in prostate cancer therapy. Clin Cancer Res 2011; 17: 5379-91.
[14]
Siddique HR, Kar Chowdhuri D, Saxena DK, Dhawan A. Validation of Drosophila melanogaster as an in vivo model for genotoxicity assessment using modified alkaline Comet assay. Mutagenesis 2005; 20: 285-90.
[15]
Fatma H, Maurya SK, Siddique HR. Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance. Semin Cancer Biol 2020.
[http://dx.doi.org/10.1016/j.semcancer.2020.11.008] [PMID: 33220458]
[http://dx.doi.org/10.1016/j.semcancer.2020.11.008] [PMID: 33220458]
Related Books
Frontiers in Clinical Drug Research - Anti-Cancer Agents
NEOPLASIA and FERTILITY
Breast Cancer: Current Trends in Molecular Research
The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo
Nanotherapeutics for the Treatment of Hepatocellular Carcinoma
Topics in Anti-Cancer Research
Frontiers in Clinical Drug Research - Anti-Cancer Agents
Modern Cancer Therapies and Traditional Medicine: An Integrative Approach to Combat Cancers
Herbal Medicine: Back to the Future
Thrombosis in Cancer: A Medical Professional's Guide to Cancer Associated Thrombosis
Article Metrics
16
2
1
1